KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Announces U.S. Launch of PediFoot Deformity Correction System

OrthoPediatrics Corp. Announces U.S. Launch of PediFoot Deformity Correction System

WARSAW, Ind., Nov. 15, 2019 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the domestic launch of the PediFoot Deformity Correction System (“PediFoot”), following 510(k) clearance by the U.S. Food and Drug Administration (FDA) in August.

The PediFoot system is the first pediatric-specific system to treat deformities of the foot.  Within the OrthoPediatrics product portfolio, this system offers the smallest plates and screws, which enable greater effectiveness in addressing cavus foot, flatfoot, clubfoot, and hallux valgus foot deformities. More specifically, the sophisticated system is designed to focus on lateral column lengthening, calcaneal slide osteotomies, opening and closing wedge osteotomies, and arthrodesis procedures. To optimize fixation in these procedures, PediFoot is the first OrthoPediatrics system to offer StarLoc™, a variable angle locking screw technology. In addition, patients will benefit from the innovative instrumentation which flexibly follows the anatomic movement of the bones during the correction process.

The system also includes PediPedal, a combination of non-slip platforms and handle that assist the surgeon in taking repeatable, simulated weight bearing x-rays intraoperatively during surgery.

“We are excited to commence the domestic launch of our PediFoot Deformity Correction System,” commented Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction. “Designed with a team of eminent pediatric orthopedic surgeons, this system addresses four of the most common pediatric foot deformities. With a heightened focus on instrumentation and intra-operative ease, the entire system is contained in one tray with innovative instrumentation that aids in reproducible correction and optimizes time in the operating room. This is the first of many launches to address pediatric foot and ankle procedures.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 32 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States.

Investor Contacts

The Ruth Group

Tram Bui / Emma Poalillo

(646) 536-7035 / 7024

/

EN
15/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences. Event: TD Cowen 46th Annual Health Care Conference Format: Fireside Chat Date: Tuesday, March 3, 2026Time: 1:10 pm ET Event: The Citizens Life Sciences Conference Format: Fireside Chat Date: Tuesday, March 10, 2026Time: 10:10 am ET An audio webcast of the ...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financ...

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Fina...

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Inv...

 PRESS RELEASE

OrthoPediatrics Announces Expanded Enabling Technology Market Opportun...

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its partner, iotaMotion, has received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. The system is now cleared for ...

 PRESS RELEASE

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue fo...

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior yearInitiates guidance for record Adjusted EBITDA in 2026 WARSAW, Ind., Jan. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch